An adverse outcome is still encountered in 45% of full-term neonates with perinatal asphyxia who are treated with moderate hypothermia. At present pharmacologic therapies are developed to be added to hypothermia. In the present article, these potential neuroprotective interventions are described based on the molecular pathways set in motion during fetal hypoxia and following reoxygenation and reperfusion after birth. These pathways include excessive production of excitotoxins with subsequent over-stimulation of NMDA receptors and calcium influx in neuronal cells, excessive production of reactive oxygen and nitrogen species, activation of inflammation leading to inappropriate apoptosis, and loss of neurotrophic factors. Possibilities for pharmacologic combination therapy, where each drug will be administered based on the optimal point of time in the cascade of destructive molecular reactions, may further reduce brain damage due to perinatal asphyxia.
Introduction
Perinatal asphyxia in the near-term and full-term infant is still one of the most important causes of neonatal death and adverse motor and cognitive outcome and has an incidence of 2-20 in every 1000 live born infants, depending in which part of the world they are born. 1, 2 There is increasing evidence that not only the actual period of antenatal and/or perinatal hypoxia-ischemia (HI) affects the neuronal cells, but also reoxygenation and reperfusion upon and after birth add substantially to delayed apoptotic and necrotic neuronal cell death due to secondary energy failure. This delayed brain damage may proceed up to days or even weeks after birth. 3, 4 At the same time this biphasic or even triphasic pattern of brain damage creates a "therapeutic" window, which is believed to range from birth up to 6 h of life, during which neuroprotective strategies can prevent or reduce the full consequences of delayed brain damage. [4] [5] [6] Up to now, the only established postnatal therapy to achieve this goal to a certain extent is moderate hypothermia. 7, 8 Although the composite adverse outcome was reduced, an adverse
Available online at www.sciencedirect.com Seminars in Perinatology www.seminperinat.com outcome of 45% is still high 8 and it is conceivable that the outcome can be improved further when moderate hypothermia will be combined with other neuroprotective strategies. In order to achieve this goal it is important to delineate the potentially harmful cascade of molecular pathways induced by fetal hypoxia and upon and after reoxygenation and reperfusion. With this knowledge additional pharmacotherapeutical interventions can be considered which may be capable to inhibit these destructive mechanisms. In this article we will particularly focus on those pharmacological interventions which can be expected to be effective in the human infant within the near future. Information of proposed dosages of the drugs and gasses discussed in this article will be provided, when available, in a separate table (Table) .
Destructive molecular pathways initiated during and after HI 1. Fetal hypoxia, an important determinant of perinatal asphyxia, sets in motion the excessive production of excitatory neurotransmitters which gives rise to the activation of N-methyl D-aspartate (NMDA)-and voltage-regulated ion channels on the cell membranes resulting in a surge of extracellular calcium into neuronal and microglial cells and astrocytes. 9, 10 This will not only lead to direct cell damage but also to a drop in the intra-and intercellular pH leading to production of proradicals liberated from their binding proteins and accumulation of xanthine.
2. Upon reoxygenation and reperfusion xanthine will be metabolized to uric acid at the expense of excessive formation of the superoxide free radical (O 2À d ), which plays a central role in the further formation of free radicals and toxic compounds [11] [12] [13] : it reacts with proradicals such as non-protein bound iron to form the very toxic hydroxyl free radical (OH • ).
14 It furthermore reacts with nitric oxide (NO • ), because of the HI-increased formation of neuronal and later also inducible nitric oxide synthase (nNOS; iNOS), 15, 16 to form the toxic peroxynitrite (ONOO À ).
The initially high levels of excitatory neurotransmitters and the surge of free radicals, especially upon and early after reperfusion and reoxygenation contribute to activation of transcription factors such as nuclear factor kappa B (NFkB) and c-jun N-terminal kinase (JNK) with subsequent activation of an inflammatory response with abundant formation of pro-and anti-inflammatory cytokines, and leading to production of iNOS setting in motion a pre-apoptotic pathway with further (delayed) brain damage. [17] [18] [19] 3. Finally, a substantial part of the delayed brain damage is related to downregulation of the formation of neurotropic, maturational, and growth factors inhibiting neurogenesis and repair. 20, 21 In the Figure A , the four patterns of above mentioned destructive molecular pathways are schematically depicted as a function of postnatal age. The proposed pharmacological interventions as described below will be discussed on basis of the course of the postnatal time pattern of these pathways.
Pharmacologic neuroprotective strategies (on top of hypothermia)
Antenatal neuroprotective therapy
The formation of excitatory neurotransmitters, free (pro-) radicals starts already during the actual hypoxia and accelerates upon birth. In this setting antenatal therapy via the mother can be considered to be the "first line of defense," at least when fetal hypoxia has been recognized. The only drug investigated in a randomized blinded clinical trial in pregnant women just before delivery and diagnosed with fetal hypoxia is the xanthine-oxidase inhibitor allopurinol and its active metabolite oxypurinol. 22 Allopurinol and oxypurinol readily pass the placenta and are detectable in umbilical blood in therapeutic concentrations as early as 20 min after maternal oral or intravenous administration. 23 Especially in high dosages allopurinol is supposed to be a free-iron chelator and free-radical (hydroxyl) scavenger.
24,25
Based on short-term outcome markers, allopurinol has been shown to be potentially effective, but effects were gender specific: only females showed benefit from antenatal therapy with allopurinol. 26 Sex differences with respect to neuroprotective therapy after HI were already suggested in earlier reports [27] [28] [29] A drawback of the study was that in the vast majority of fetuses hypoxia was mild. The long-term results of this study are currently under investigation. An earlier pilot study preceding the randomized trial by the same investigators in fetuses with more severe hypoxia showed the potency of allopurinol as a neuroprotective agent.
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A second potentially promising neuroprotectant is the noble gas xenon. Xenon is an antagonist of the NMDA , peroxynitrite). (B) Possible combination therapy paradigms with optimal points of time for start and cessation of pharmacological compounds directed to the different destructive molecular pathways. If recognized, maternal allopurinol can be started during substantial fetal hypoxia and continued during early life. Free radical and ONOOÀ formation can be reduced by free radical scavenging by melatonin, rhEPO and 2-IB respectively (start within 6 h of age), whereas anti-inflammatory activity can be challenged by melatonin and rhEPO up to 48 h of age; reduction of apoptosis and stimulation of production of (neuro)trophic factors can be achieved with rhEPO, IGF-1 and/or (M)SCs, administered for longer periods (days or weeks) (rhEPO, recombinant human erythropoietin; 2-IB, 2-iminobiotin; IGF-1, insulin growth factor-1; (M)SCs, (mesenchymal) stem cells). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) receptor but has also strong anti-apoptotic properties. [31] [32] [33] And, most important, xenon is considered to be a safe anesthetic which rapidly crosses the placenta. 34 This makes xenon very attractive for its use in mothers undergoing an emergency cesarean section because of severe fetal hypoxia. 35 However, unlike for postnatal use (see also below), there are to date no studies performed to investigate and confirm the neuroprotective actions of xenon as an antenatal neuroprotective strategy. Ascorbic acid (vitamin C), 36, 37 tetrahydrobiopterin (BH4), 38 phenobarbital, 39 N-acetylcysteine, 40 and melatonin 41 were or are proposed to be of value for antenatal neuroprotection, but an unfavorable safety profile (N-acetylcysteine), inconclusive or disappointing clinical results (vitamin C and phenobarbital) or no clinical studies (melatonin) prevent clinical use of these compounds up to now. 42 Magnesium has been shown to reduce excitotoxicity following hypoxia-ischemia by inhibition of the NMDA-receptor/ion channel complex. 43 The mode of action of magnesium in fetal neuroprotection remains largely unknown, since in vivo concentrations are much lower than those needed for inhibition of the NMDA receptor. 44 Although magnesium administration before 33 weeks of gestation to women with high-risk pregnancies have resulted in a reduction of cerebral palsy and adverse motor development 45 is in term pregnancies no definite beneficial effects of maternal magnesium demonstrated.
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Early postnatal neuroprotective therapy
As summarized above, the immediate postnatal reoxygenation-reperfusion phase leads to further to the activation of NMDA-and ion channels with subsequent calcium influx in neurons, excessive formation of free radicals, and the nNOSrelated toxic ONOO À .
Therefore, NMDA/ion channel antagonists, inhibition of xanthine-oxidase, prevention of nNOS (and subsequently also of iNOS) formation, and chelation of pro-radicals are critical to reduce early reperfusion-reoxygenation damage to the brain.
In recent studies noble gases, which are NMDA/ion channel antagonists, have been used for neuroprotection. Xenon, a known anesthetic has been tested in several experiments. [47] [48] [49] Xenon shows a rapid passage of the blood-brain barrier, and has no reported negative cardiovascular side effects. Xenon as such did not appear to be effective, but in combination with hypothermia neuroprotection by xenon has been demonstrated in several species. 42 In a feasibility study 14 neonates with perinatal asphyxia and therapeutic hypothermia received up to 50% xenon for 18 h and no adverse side effects were demonstrated. 50 Several dosing strategies of xenon are explored, including 50% xenon for 18 h (ClinicalTrials: NCT02071394), or 30% xenon for 24 h (ClinicalTrials: NCT00934700). At present follow-up of the patients included in these studies is ongoing.
Prolonged use of xenon in neonates faces several challenges. Most important of all xenon is very expensive, and therefore adjustments in neonatal ventilators need to be made to recruit xenon. 51 To reduce loss of xenon cuffed tubes are used which might enhance the risk of tracheal lesions.
To avoid these latter potential problems other noble gases have been tested for neuroprotective properties. 52 In particular argon was neuroprotective after neonatal brain hypoxiaischemia. 52, 53 A study in piglets showed cardiovascular stability of argon administration after hypoxia and during therapeutic hypothermia. 54 Blood levels of argon could be measured and were dose dependent. The noble gas argon is much cheaper than xenon, and may be a useful alternative for xenon. Another clinically potential pharmacologic intervention for the near future may be inhibition of excessive NOS formation. Whereas non-selective inhibition of NOS is detrimental, probably due to vasoconstriction, selective inhibition of neuronal and inducible NOS appears to be neuroprotective.
55,56 A selective nNOS inhibitor that has been used in many experiments is 7-nitroindazole. However, some additional inhibition of eNOS may occur, which is not desirable in cerebral hypoxia-ischemia. 57 Therefore, compounds have been developed that have much higher in vitro specificity and potency than available nNOS inhibitors. 58 Combination of a selective nNOS inhibitor with a selective iNOS may be more effective. 2-Iminobiotin is an in vitro inhibitor of both nNOS and iNOS and provides neuroprotection after hypoxiaischemia in neonatal rat and pig models, although the neuroprotection may be independent of NOS inhibition in vivo.
59-61
A phase 2 study is ongoing (ClinicalTrials.gov Identifier: NCT01626924). Allopurinol may have its most optimal indication for antenatal use in case of proven fetal hypoxia, especially to inhibit the excessive production of xanthine-oxidase during birth. However, several clinical studies reporting the use of intravenous allopurinol in the (early) postnatal period showed a beneficial effect on short-term cerebral biomarkers and even on long-term outcome, especially in moderately asphyxiated infants and seems to have no serious adverse effects. [62] [63] [64] However, in a Cochrane review in 2008 no conclusions could be drawn about the efficacy of postnatal neuroprotection with allopurinol after perinatal asphyxia since the clinical trials reported up to now were underpowered. 65 An international trial aiming to treat asphyxiated newborns on the resuscitation table with allopurinol is under consideration at present. Other neuroprotective drugs with potential for future clinical use, particularly in the early postnatal period, are melatonin and N-acetylcysteine (NAC). Melatonin has been thought to have anti-oxidative properties on top of its antiinflammatory and anti-apoptotic effects. [66] [67] [68] Experimental studies showed neuroprotective properties in the mid-and late-gestation sheep fetus. [68] [69] A small clinical study in asphyxiated newborns showed a reduction of free radical formation. 70 Although melatonin seems to be safe and without serious adverse effects, there is no consensus on the optimal dosing. 71 NAC is a precursor of glutathione, has the properties of an anti-oxidant and is supposed to exert also a direct free radical scavenging activity. 72 The neuroprotective properties are controversial and (hemodynamic) adverse reactions are reported. 42 Neuroprotective actions of NAC have been reported in neonatal rodents as well as in piglets with and without additional hypothermia. 73, 74 Although clinically used in preterm newborns, mostly in relation with prevention of bronchopulmonary dysplasia, no clinical studies are done yet in asphyxiated (term) newborns. Studies with tetrahydrobiopterin being a neuroprotective agent after perinatal asphyxia are actually non-existent, although its safety profile is very attractive for further study in relation with perinatal hypoxia-ischemia. 42 Topiramate, a well-known anticonvulsant, has sparsely investigated for its neuroprotective actions after birth asphyxia. 75 A safety and efficacy study (NeoNATI) was recently completed in combination with moderate hypothermia 76 (ClinicalTrials: NCT01241019). Postnatal magnesium administration has not been uniform in demonstrating neuroprotective effects of magnesium in full-term affected neonates. 44 Earlier trials for neuroprotection after perinatal hypoxia-ischemia were discontinued because Magnesium administration carried the risk of severe hypotension. 77 However, currently studies are performed of magnesium combined with moderate hypothermia (ClinicalTrials: NCT02499393 and NCT01646619).
Anti-inflammatory and anti-apoptotic therapy
The transcription factor nuclear factor kappa B (NFkB) regulates the expression of genes involved in inflammation and apoptotic activity. Its activation gives rise to abundant formation of pro-and anti-inflammatory cytokines, production of inducible NOS (iNOS), and inappropriate apoptosis.
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Of the neuroprotective agents with an anti-inflammatory action and a potential for clinical application in the near future erythropoietin (EPO) is the most and up to now only attractive candidate. 78 EPO exerts its anti-inflammatory action after binding to its receptor (EPOR) which is expressed on the membranes of neurons, astrocytes, and microglial cells. 79 Recombinant Human EPO (rhEPO) is already quite extensively used in the very and extremely preterm infant in increasing dosages and in a pilot study in term neonates with neonatal stroke and has a safe pharmacological profile. 80, 81 Numerous experimental studies in experimental studies in different neonatal species showed its neuroprotective properties with respect to post-hypoxic-ischemic brain damage. 79 Clinically a pilot study of 45 patients showed that treatment of asphyxiated newborns with rhEPO seemed safe and feasible. 82 A blinded randomized phase III trial in asphyxiated term newborns in China showed that repeated (low) doses of intravenous administered rhEPO decreased the incidence of disabilities at 18 months of age, although there was a suggestion that females but not necessarily males benefit from this therapy. 83 A pharmacokinetic study in 24 severely asphyxiated newborns who underwent hypothermia were treated with additional rhEPO and showed that a quite high dose of 1000 U/kg was well tolerated. Plasma concentrations were similar as reported in earlier neuroprotective studies in newborn animals. 84 A randomized trial with hypothermia with high-dose rhEPO as add-on therapy is currently running (ClinicalTrials: NCT01913340) These randomized trials in newborns undergoing hypothermia are necessary to ultimately confirm the neuroprotective actions of additional rhEPO and to determine the optimal timing, dose, and duration of treatment. Up to now no serious adverse effects are reported during the clinical use of rhEPO in (preterm) newborns. However, especially when higher dosages are used and/or administered for longer periods of time there may be concerns with respect to safety and more research is warranted here. 85, 86 EPO derivatives which have less unwanted effects such as asialo-EPO 87 or longer half-life such as darbepoietin 88 are less well investigated but may be clinically interesting because of their specific properties. In addition to its anti-oxidative and free radical scavenging actions melatonin is also supposed to have antiinflammatory properties by preventing activation and translocation of NFkB to the nucleus 89 (also see above).
The development of inhibitors of pro-inflammatory cytokines 90 or anti-apoptotic strategies (NFkB inhibition) 91 are extremely interesting and potentially very forceful but beyond the focus of this review.
Suppletion of (neuro)trophic and growth factors
Neurotrophic, maturational, and growth factors are important for a normal development of the immature brain by stimulation of the endogenous neurogenesis. 92 Downregulation of these factors occurs after severe perinatal HI and may be deleterious for recovery and proper development of the post-asphyxial newborn brain. Besides the anti-oxidative and anti-inflammatory actions of EPO, as described above, it has been supposed that EPO has also important neurotrophic properties. [93] [94] [95] It is suggested that for a sustained effect of EPO on neuroand angiogenesis and thus improved long-term outcome higher doses (up to 5000 U/kg) and prolonged periods of treatment are necessary, which may raise safety concerns. 85, 86 An important related issue is the role of hypoxia-induced factor 1α (HIF-1α), activated during and upon hypoxia-ischemia, which gives rise to the formation of transcriptional targets, leading to an enhanced production of EPO and endothelial growth factor and consequent brain repair. 96 Other neurotrophic factors such as IGF-1, basic fibroblast growth factor (bFGF), and BDNF in experimental studies in neonatal animals are reported to be also effective to reduce post-asphyxial brain damage. 97, 98 However, use of autologous or allogeneic mesenchymal stem cell therapy after perinatal hypoxia-ischemia seems more effective in this respect but is discussed separately in this issue.
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Combination therapy, the way to go
It is unrealistic to assume that single or add-on therapy without taking into account the time frame of the sequential potentially destructive molecular pathways, will be the ultimate answer toward a substantial reduction of brain damage after (severe) perinatal asphyxia. Moreover, appropriate dosing of the drugs, pharmacologic compounds, and gasses discussed above, the duration and site of their administration, and a possible gender specificity of the compounds used needs ongoing research. However, when we can solve the above mentioned questions and are able to determine the optimal post-ictal time of intervention in each specific molecular pathway, a major achievement can be added to the treatment of hypoxia-ischemia-induced neonatal encephalopathy. 78 The Figure B shows a tentative (pharmacological) treatment paradigm, which may have clinical relevance in the (near) future.
Concluding remarks
Ongoing research in neuroprotective pharmacology after perinatal asphyxia has offered us potentially forceful compounds to further reduce and to repair damage to the immature brain during and after severe birth asphyxia as add-ons to the only established neuroprotective therapymoderate hypothermia. There is still a long way to go to determine the optimal dose of these compounds and to find the optimal point of time of start and duration of pharmacological therapy. A definite decision on the clinical use depends, of course, first of all on the safety profile of the potentially neuroprotective drug. r e f e r e n c e s
